Hmm. Interesting how this works. Remdesivir met Primary Endpoint in s/c trial, yet the drug has no efficacy for s/c patients. Hmm, and Leronlimab did not meet Primary Endpoint in s/c trial, yet it does display efficacy for critical patients. Maybe this has something to do with trial design, Primary Endpoint selection and who got advice to make Endpoint changes, and who was advised not to make Endpoint changes, at interim analysis intervals?

Hey, uh, if you make this change to your Primary Endpoint, you will get an acceptable p value. Yes, it will be easy to meet, not really very relevant, but, easy to meet. Efficacy? Side Effects? For LL... Hey, no need to make any changes, you are trending toward meeting your Primary Endpoint.